Mediso Orvosi Berendezes Fejleszto es Szerviz Kft.

Their core work

Mediso is a Budapest-based medical imaging technology company specializing in the development and manufacture of preclinical multimodal imaging systems — SPECT, PET, CT, and optoacoustic/photoacoustic scanners used in biomedical research. Their core product offering supports in vivo imaging of small animals and biological specimens, making them a hardware and methodology provider to academic and pharmaceutical research groups. In the iNanoBIT project, they contributed imaging capabilities to track nanomolecule-labeled beta-cells and pancreatic islets in the context of diabetes and xenotransplantation research. They are effectively an instrumentation specialist: they bring the scanners, the imaging protocols, and the technical know-how that researchers need to visualize what is happening inside living biological systems.

What they specialise in

How they've shifted over time

With only two projects — both starting in 2017 — there is no meaningful temporal shift to analyse. All keyword evidence comes from iNanoBIT (2017–2023), which dominates their H2020 footprint; the HYBRID project contributed no resolvable keywords. Their profile is therefore a snapshot of a single deep engagement rather than an evolution. If a trend exists, it points toward increasing specificity at the intersection of multimodal preclinical imaging and biological cell tracking, but this cannot be confirmed from H2020 data alone.

Mediso appears to be deepening its position as an instrumentation partner for nano-biomedical research, particularly where non-invasive in vivo imaging of cells or nanoparticles is needed — a niche that is growing as regenerative medicine and cell therapy move toward clinical translation.

How they like to work

Mediso participates exclusively as a specialist contributor or third party, never as a coordinator — consistent with a technology company that brings a defined product or capability rather than leading research agendas. Their engagement in iNanoBIT, a large RIA consortium with 31 partners across 10 countries, shows they are comfortable operating within complex multi-stakeholder projects while maintaining a focused technical role. Working with them likely means procuring access to their imaging systems, methodological support, and data interpretation expertise rather than a broad R&D partnership.

Mediso has built connections with 31 unique consortium partners across 10 countries through just two projects, almost entirely via the large iNanoBIT RIA network. Their geographic spread is European, with a likely concentration in Central-Eastern Europe and major biomedical research hubs in Germany, the Netherlands, and Scandinavia given the nature of iNanoBIT.

What sets them apart

Mediso occupies a rare niche as one of the very few SMEs in Central-Eastern Europe that both manufactures and provides scientific support for preclinical SPECT/PET/CT and photoacoustic imaging systems — hardware that most academic research groups must purchase or access through core facilities. For consortium builders in regenerative medicine, cell therapy, or nanomedicine, Mediso offers something that pure research institutions cannot: production-grade imaging instrumentation combined with in-house application expertise. This makes them an unusually self-contained technology partner for projects that need imaging as a core methodology rather than an afterthought.

Highlights from their portfolio

• iNanoBIT
  A EUR 795K RIA project spanning 2017–2023 that combined nanotechnology with beta-cell transplantation research for diabetes — Mediso's largest and most technically specific H2020 engagement, demonstrating their imaging systems at the frontier of regenerative medicine.
• HYBRID
  An MSCA Innovative Training Network (2017–2021) where Mediso participated as a third party, signalling their interest in training the next generation of researchers and extending their reach into the academic talent pipeline beyond equipment sales.